Centro De Ingenieria Genetica Y Biotecnologia

Biorec S.a.

Centro De Ingenieria Genetica Y Biotechnologia

Biorec B.v.

Lila Rosa Castellanos Serra

Gerardo Enrique Guillen Nieto

Luis Javier González López

Boris Ernesto Acevedo Castro

Daniel Eduardo Gomez

Daniel Fernando Alonso

Jeovanis Gil Valdés

Lázaro Hiram Betancourt Núñez

Aniel Sánchez Puente

Yassel Ramos Gómez

Jorge Fernández De Cossio Dorta Duque

Vladimir Besada Pérez

Osvaldo Reyes Acosta

Silvio Ernesto Perea Rodriguez

Raimundo Ubieta Gómez

Sonia Gonzalez Blanco

Celia Berta Fernandez Ortega

Yasser Perera Negrin

Dionne Casillas Casanova

Taimi Emelia Paneque Guerrero

Marta Dubed Echevarria

Leonor Margarita Navea Leyva

Carlos Antonio Duarte Cano

Arielis Rodríguez Ulloa

Jorge Victor Gavilondo Cowley

Mónica Bequet Romero

Raimundo Ubieta Gomez

Manuel Selman-Housein Sosa

Viviana Falcon Cama

Eduardo Martinez Diaz

Viviana Falcón Cama

Raúl Gómez Riera

Rolando Pajón Feyt

Gloria Veliz Rios

José Garcia Suárez

Anna Caridys Ramírez Suarez

Caridad Anais Gasmuri González

Gloria Véliz Rios

Jesús Reyes González

Aniel Sanchez Puente

Rolando Pajon Feyt

Arielis Rodriguez Ulloa

Jeovanis Gil Valdes

Anna Caridys Ramírez Suárez

Yasser Perera Negrín

Silvio Ernesto Perea Rodríguez

Maria Del Carmen Abrahantes Pérez

Anna Caridys Ramirez Suarez

Olivia Niebla Perez

Evelin Caballero Menendez

Darién Garcia Diaz

Gretel Calle Jorge 18 Sardinas Garcia

Lázaro Hiram Betancourt Nunez

Evelin Avd 31A Edif Caballero Menéndez

Gerardo E Guillén Nieto

Darién García Díaz

Olivia Niebla Pérez

Sonia Calle 184 3112 González Blanco

Gretel Calle Jorge 18 Entre Sardiñas García

Marta Dubed ECHEVARRÍA

Luis Javier GONZÁLEZ LÓPEZ

Viviana FalcÓn Cama

Luis Javier Gonzalez Lopez

Raul Gomez Riera

Caridad Anais Gasmuri Gonzalez

Jose Garcia Suarez

Maria Del Abrahantes Perez

Jesus Reyes Gonzalez

Monica Bequet Romero

Vladimir Besada Perez

Jorge Fernandez De Cossio Dorta Duque

Lazaro Hiram Betancourt Nunez

Yassel Ramos Gomez

The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the the proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, including peptides and/or interfering RNA and/or lipidic compounds, the agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection.

Method for inhibiting HIV replication in mammal and human cells

This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs

This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton.

This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1-100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's 'in vivo' administration has antitumoral, antiangiogenic and protective effect against malignant tumors.

Pharmaceutical composition containing polypeptide fragments of serralysins

Growing community of inventors

Ciudad de la Habana, Cuba

Lila Rosa Castellanos Serra